Effect of Nintedanib on patient survival

Nintedanib (Nintedanib) is a targeted drug mainly used to treat idiopathic pulmonary fibrosis (IPF) and some other types of lung diseases, such as non-small cell lung cancer (NSCLC). Its mechanism of action is to prevent fibrosis and cancer cell proliferation by inhibiting multiple tyrosine kinases. For patients with idiopathic pulmonary fibrosis, the use of nintedanib can effectively slow down the progression of the disease, thereby improving the patient's quality of life and prolonging survival.

In clinical studies, nintedanib has been shown to significantly slow the loss of lung function, which is critical for patients with idiopathic pulmonary fibrosis. IPF is a serious disease that causes the lungs to gradually stiffen and restrict ventilation. The survival period of patients is usually very short. Without treatment, many patients may only survive 3 to 5 years after diagnosis. However, by using nintedanib, the decline of lung function can be effectively delayed and the progression of the disease can be slowed. According to research, nintedanib can extend the survival of patients with idiopathic pulmonary fibrosis by several years. Although it cannot completely cure the disease, it greatly improves the patient's quality of life and survival by slowing down the course of the disease.

For patients with non-small cell lung cancer, the application of nintedanib in combination chemotherapy has also shown certain efficacy. Especially for certain types of advanced lung cancer, nintedanib can extend the overall survival of patients (OS) by inhibiting the growth and spread of tumor cells. However, the specific survival extension also depends on the patient's physical condition, the stage of the cancer and whether there are other complications. Although nintedanib has shown some survival benefit in the treatment of advanced non-small cell lung cancer, such improvements in efficacy are usually relative rather than absolute, so the magnitude of survival improvement varies from patient to patient.

Overall, nintedanib can effectively delay the progression of certain lung diseases, especially idiopathic pulmonary fibrosis, improve patients' quality of life, and prolong their survival. For patients with advanced lung cancer, although treatment has a certain effect, the specific number of years of survival is still affected by many factors. When using nintedanib, patients need to work closely with their doctors to regularly check lung function and other related indicators to ensure maximum benefit from treatment.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib